Cross-Cutting Engineering

Stability and Accelerated Aging

Evaluate product, formulation, package, and device performance over time under controlled conditions to support shelf-life and change-control decisions.

We run accelerated and real-time conditioning with scheduled pulls, chamber records, and paired performance or chemistry tests to quantify trends.

ISO 17025ICH Q1A (R2)USP <659>FDA stability guidanceReviewed 2026-05-16
Request a quoteSubmit a sample

Purpose & when to use

ARE Labs uses environmental chambers, scheduled pull points, and paired performance or analytical testing to measure changes in products, formulations, devices, and packages over time. Programs can align with ICH Q1A (R2), USP <659>, and FDA stability guidance. The study record preserves ISO 17025 traceability across sample identity, chamber records, method controls, and reported uncertainty.

  1. ICH Q1A (R2) accelerated programs for inhalation products using environmental chambers and PSD or emitted-dose pulls to estimate early shelf-life risk.
  2. FDA stability guidance real-time programs for nasal sprays, aerosols, or devices using chamber storage and periodic performance or chemistry readouts.
  3. USP <659> storage-condition selection for packaged products using temperature/RH chambers, excursion logs, and defined pull schedules.
  4. ICH Q1B photo-stability or material-aging screens using UV exposure, retained samples, and paired chemistry or appearance checks.
  5. USP <1118> transport-stress linkage for packaged devices using cyclic abuse profiles, post-stress storage, and acceptance criteria.

Use stability and accelerated aging studies when time, storage conditions, material changes, or shipping exposure could affect product performance. The method plan defines the conditioning environment, pull schedule, paired tests, and evidence needed for shelf-life or design-change decisions.

Built for products, packages, and device programs

Stability programs cross pharmaceutical, device, packaging, and consumer-product boundaries. The same controlled-condition framework can support ICH, USP, FDA, and product-specific acceptance criteria.

  • Inhalation productsMDI, DPI, nebulizer programs
  • Nasal spraysPump and unit-dose formats
  • Consumer aerosolsSprays, valves, packages
  • Medical devicesMaterials and performance attributes
  • PackagingConfigurations and storage protection

Instrumentation & measurement ranges

Conditioning and readout platforms are selected for the protocol. Storage state, pull schedule, and paired test methods are documented before the study begins.

25 - 40 Cstorage

Environmental chambers (temperature/RH)

Controlled storage for real-time, intermediate, and accelerated programs with condition logging, chamber verification, and documented excursion handling.

20 - 60 Cexcursion

Cyclic stress and abuse protocols

Temperature cycling, humidity stress, and fit-for-purpose excursions used when shipping, distribution, or expected-use conditions may drive performance drift.

1 - 2 kLuxexposure

UV exposure for photo-stability

Optional light exposure for ICH Q1B-style photo-stability or material-aging questions when the product, package, or formulation has light sensitivity risk.

0 - 12 motrend

Paired performance and chemistry readouts

PSD, emitted dose, plume, VOC/by-product, HPLC assay, impurity, appearance, or package checks coordinated at defined pulls.

Test method options

MethodStrengthsTradeoffAligned with
Accelerated aging program (environmental chambers)
  • Faster drift signal from elevated temperature/RH conditions aligned to ICH Q1A (R2) and FDA stability guidance.
  • Supports early shelf-life estimates, formulation screens, and packaging comparisons before real-time data mature.
Requires documented acceleration assumptions, endpoint limits, and bounds for extrapolation.
ICH Q1A (R2)FDA stability guidance
Real-time stability program (scheduled pulls)
  • Most representative evidence for storage claims under ICH Q1A (R2), USP <659>, and FDA stability guidance.
  • Pull calendars, retains, chamber logs, and paired readouts create a traceable long-term record.
Decision timing is slower, so sample allocation and pull logistics must be disciplined.
ICH Q1A (R2)USP <659>FDA stability guidance
Photo-stability and material-aging screen (UV exposure)
  • Targets light-driven appearance, assay, impurity, or material changes under ICH Q1B / Q1C exposure framing.
  • Pairs exposed and protected samples so packaging protection or formulation sensitivity is visible.
Light exposure does not replace temperature/RH stability unless the protocol states that limited question.
ICH Q1B / Q1C
Transport stress linkage (cyclic abuse profiles)
  • Connects distribution excursions to post-stress performance under USP <1118> and product-specific acceptance criteria.
  • Useful for package changes, device revisions, and shipping-lane questions before full real-time data arrive.
Requires a defined stress profile and acceptance criteria before samples enter conditioning.
USP <1118>
Performance-plus-chemistry trending (paired readouts)
  • Links physical performance drift to assay, impurity, VOC, or by-product changes across pull points.
  • Supports ICH Q1B / Q1C package or container questions when configuration changes may affect stability.
Coordinated sampling increases method-control needs across storage, performance, and chemistry teams.
ICH Q1B / Q1C

Setup configurations

A stability study begins with a written protocol defining storage conditions, package configuration, pull timing, sample allocation, acceptance criteria, and readout methods. This setup links the storage record to the testing performed at each pull, allowing observed trends to be interpreted against the sample's documented condition and handling history.

Environmental controls

Temperature/RH targets, chamber assignment, condition logging, calibration checks, and excursion review plan.

Sample numbers

Pull schedule, retain allocation, replicate count, destructive-test needs, and replacement rules for missed pulls.

Sample matrix

Formulation, device revision, packaging configuration, orientation, and storage state documented before conditioning.

Exposure profile

Accelerated, real-time, photo-stability, transport, or cyclic-stress profile selected for the decision under study.

Chain of custody

Receipt, storage transfer, pull execution, readout handoff, and final disposition recorded for each sample group.

Quality anchors for stability evidence

Before the first sample enters storage, the stability program needs a clear quality and regulatory framework. These anchors define how conditions and pulls are documented, how acceptance criteria and exceptions are handled, and how results are reported.

  • ISO 17025AccreditedTesting-laboratory competence, traceable records, and method control.
  • ICH Q1A (R2)AlignedStability condition selection, pull timing, and shelf-life evidence.
  • USP <659>AlignedPackaging and storage condition terminology for articles.
  • FDA stability guidanceAlignedSubmission-facing stability expectations and documented rationale.

Key data outputs & reporting

Each stability program provides condition histories, pull-point results, and trend interpretation for shelf-life, storage, design-change, or shipping decisions. The report documents the protocol, assumptions, acceptance criteria, chamber events, paired test methods, and contributors to uncertainty. Results are organized by time, condition, lot, package, device revision, endpoint, and acceptance outcome, giving the customer a clear record of what changed and under which study conditions.

Primary outputs

  • Trend tables for key performance attributes such as PSD, emitted dose, plume, appearance, VOCs, assay, or impurities.
  • Condition history, chamber excursions, pull execution records, and sample identity checks tied to each result set.
  • Shelf-life, re-test interval, or design-change discussion with assumptions, limits, and observed drift rates stated.

Deliverables

#FormatContents
01PDF reportProtocol, conditions, controls, results, trend interpretation, and stated assumptions.
02CSV / XLSX datasetsPull-point results, chamber logs, trend tables, and calculated deltas.
03FiguresTrend plots, overlays, excursion summaries, and condition comparisons.
Extended deliverables · multi-arm comparability · stability · predicate studies
  • Shelf-life appendix — Drift rates, confidence intervals, and shelf-life or re-test interval rationale.
  • Change-control pack — Side-by-side trends for package, material, formulation, or device revisions.
  • Transport linkage summary — Stress profile, post-stress checks, and comparison to unstressed retains.

QA / QC & data integrity

Stability data are useful only when the storage conditions and pull history are defensible. QA / QC controls cover chamber readiness, sample identity, pull execution, paired method controls, and exception handling from receipt through final reporting. The study file keeps the trend data with the chamber conditions, handling records, and method information needed to interpret them.

Chamber calibration, verification, and continuous condition logs reviewed against the protocol.

Pull-point checklists, sample identity verification, and chain-of-custody records for every sample group.

Method QC for paired readouts, including controls, calibration checks, blanks, repeats, or recovery checks as applicable.

Defined acceptance criteria for chamber excursions, outliers, missed pulls, and trend flags.

Storage configuration photos or diagrams when orientation, package state, or device setup affects interpretation.

RESEARCH / THIS WORK IN PRACTICE

Real studies. Measured evidence.

Explore published studies connected to stability and accelerated aging. Each explains the study question, approach and findings.

View related studies (1)
Packaging & Stability

Cosmetic wand-package testing: temperature and altitude

The study separated temperature-related formulation and applicator behavior from reduced-pressure leakage risk in three anonymized package variants.

Selected finding
At 40 °C, maximum losses were 93 mg, 52 mg, and 51 mg; the 93 mg result came from one anomalous unit, while the maximum among the remaining Variant A units was 46 mg.
PackagingEnvironmental simulationProduct evaluation

Study-specific findings do not guarantee performance for another product.

Why ARE Labs

ARE Labs connects technical topics to practical study design, method selection, controlled aerosol work, and reportable evidence without turning technical pages into sales pages.

Reviewed byJamie Balarashti (25 yrs - cascade & inhalation methods) - Weston Schaper (7 yrs - real-time sizing & nanoparticle work)
17025Accredited testing
900+Studies Performed
17+Years in operation
300+Clients supported

Common questions

Stability questions often come from product, quality, regulatory, packaging, and device teams deciding how much time-based evidence they need before making a claim, preparing a submission, or approving a change. The answers below address accelerated and real-time programs, condition selection, pull-point testing, transport stress, and deliverables. When a product, package, intended claim, or regulatory framework requires a different study structure, ARE Labs can help define it.

Q.Which is better, accelerated aging or real-time stability?
A.They answer different questions. Accelerated aging can reveal drift earlier and inform risk estimates; real-time stability provides evidence under representative long-term conditions. Many programs use both, with the assumptions and limits documented in the protocol and report.
Q.Can performance tests run at each pull?
A.Yes. Pull-point testing can include PSD, emitted dose, plume, VOC/by-product, appearance, assay, impurity, or package checks. We define the readouts before storage so sample numbers and timing match the decision.
Q.How are conditions and pull points chosen?
A.We start with ICH, USP, FDA, or product-specific frameworks, then account for product risk, expected drift, package configuration, and decision timing. The protocol documents the conditions, pull dates, acceptance criteria, and handling of excursions.
Q.Do you include shipping or transport stress?
A.Yes. Transport profiles can be applied before storage or evaluated as a separate stress leg. When distribution-risk evidence is needed, post-stress performance is compared with unstressed retains.
Q.What do stability deliverables include?
A.Deliverables usually include a PDF report, CSV or XLSX datasets, trend plots, chamber logs, pull records, and a discussion of drift, uncertainty, and study assumptions. Shelf-life or change-control appendices can also be included.

Standards & guidance

Stability and accelerated aging studies are scoped around the product, the decision at hand, and the applicable regulatory framework. ARE Labs treats ISO 17025 as the quality-system anchor for traceable testing and aligns the study design with ICH, USP, and FDA stability guidance where applicable. The standards below most often guide storage conditions, photo-stability, packaging, and transport-related evidence.

QA & Regulatory - Accredited

ISO 17025

Testing-laboratory competence, traceable records, calibration control, and uncertainty contributorsView standard ->Stability & Shelf Life - Aligned

ICH Q1A (R2)

Stability testing of new drug substances and products, including condition selection and pull timingView standard ->Stability & Shelf Life - Aligned

ICH Q1B / Q1C

Photo-stability and package-configuration stability considerations for light-sensitive or changed productsView standard ->Pharmacopeial - Aligned

USP <659>

Packaging and storage requirements terminology for articles and labeled storage conditionsView standard ->Pharmacopeial - Aligned

USP <1118>

Monitoring and interpreting distribution, storage, and transport conditions for pharmaceutical articlesView standard ->QA & Regulatory - Aligned

FDA stability guidance

FDA expectations for stability evidence, storage claims, and submission-facing documentationView standard ->

Related services & devices

Service

Dose Uniformity & Emitted Dose

Pairs with stability pulls when per-actuation dose or shot-to-shot variability may drift during storage.Read more ->Devices

Drug Delivery

Inhalation, nasal, and oral delivery devices often need stability evidence across formulation, actuator, or package changes.Read more ->Service

Particle Size Distribution (PSD) Testing

PSD trending can show aerosol performance drift at stability pulls for inhalation, nasal, and spray products.Read more ->Devices

Spray & Aerosol

Consumer sprays and aerosol packages use aging studies to evaluate valve, material, emission, or package drift.Read more ->